FDA
Sponsored by: StreetInsider Premium - FREE TRIAL!
Set Up E-mail Alerts For FDA » RSS Feed For FDA »BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of safety and tolerability. In addition, BCX-4208 displayed dose-dependent reductions in peripheral blood lymphocyte counts, including subsets measuring B cells (CD20), total T cells (CD3), T helper cells (CD4) and T suppressor/cytotoxic cells (CD8).
BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses.
Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
A drug designated as a Fast Track product is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to provide a therapy where none exists or provide a therapy which may offer a significant improvement in safety and/or effectiveness over existing therapy.
GTC Biotherapeutics (Nasdaq: GTCB) has been granted Priority Review from the FDA on its Biologic License Application, or BLA, for ATryn, recombinant form of human antithrombin.
Priority Review is granted to applications for products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. Under Priority Review, the FDA's target date for action on the BLA is February 7, 2009.
EPIX Pharmaceuticals (NASDAQ: EPIX) announced that Bayer Schering Pharma will transfer the worldwide commercial rights for the novel blood pool magnetic resonance angiography (MRA) agent, Vasovist(R) (gadofosveset trisodium) to EPIX. The collaboration agreement between the two parties will terminate effective March 1, 2009; until that time, Bayer Schering Pharma will continue to provide continued supply of Vasovist in the 19 countries where it is currently marketed.
According to Bayer Schering Pharma, the company is committed to ensuring that patients and physicians in the countries where Vasovist is currently marketed have continued access to Vasovist during this transition period.
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform.
ImClone Systems (NASDAQ: IMCL) submitted an application to the FDA to broaden the use of ERBITUX to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
The application, submitted on August 29, 2008, was prepared in conjunction with Bristol-Myers Squibb Company (NYSE: BMY), ImClone's partner for ERBITUX in North America. ImClone has requested Priority Review of the application, which, if granted, means that the FDA would make a decision on the application within six months. The FDA will notify ImClone whether it has accepted the submission by the end of October.
NOTE: Bristol-Myers recently offered $60 per share to acquire ImClone, but no deal has been reached yet.
More FDA
View Older Stories-
United Therapeutics (UTHR) Said FDA Accepts NDA for Inhaled Treprostinil
-
Edwards Lifesciences (EW) Receives FDA Approval for PERIMOUNT Magna Mitral Heart Valve
-
Sepracor's (SEPR) Reports Results From LUNESTA(R) Study
-
Discovery Labs (DSCO) Announces Aerosolized KL-4 Surfactant Chosen for Phase 2a Clinical Trial
-
Medivation (MDVN) In Collaboration With Pfizer (PFE) For Dimebon
-
Neurocrine Biosciences (NBIX) Announces Positive Data From Phase II Trial of Elagolix
-
Regeneron (REGN) Said ARCALYST Reduced Incidence of Gout Flares
-
Human Genome Sciences (HGSI) Reports Results of Phase 2 Trial of HGS-ETR1
-
Alexza Pharmaceuticals (ALXA) Reports Positive Phase 3 Results From AZ-004 Trails; 5 and 10 mg Doses Meet Primary Endpoint
-
Pain Therapeutics (PTIE) Receives $20M in Milestone Payments from King Pharma (KG)
-
Covidien (COV) Subsidiary Settles Patent Infringement Lawsuit with Purdue Pharma
-
Introgen Therapeutics (INGN) BLA Not Sufficiently Complete Says FDA
-
Alpharma (ALO) NDA For EMBEDA Accepted By FDA for Priority Review
-
Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
-
Amylin (AMLN) Gets A Friend After Yesterday's 25% Sell-Off
-
Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
-
Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
-
Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
-
BioDelivery Sciences (BDSI) Sees 1H09 Approval of BEMA(TM) Fentanyl
-
NexMed (NEXM) Murdered After Pulling NDA for NM100060
-
Cell Genesys (CEGE) Slammed After Halting Trial Due To Deaths
-
American Bio Medica (ABMC) Receives FDA CLIA Waived Status for Rapid TOX(R) Drug Test Product
-
Novartis (NVS) Announces Gleevec(R) Receives FDA Priority Review
-
Amylin (AMLN) Issues Detailed Statement Regarding FDA Alert on BYETTA - Shares Down Almost 9% in After-Hours
-
Eli Lilly (LLY) and Amylin (AMLN) reveal 4 additional deaths from Byetta - CNBC
-
Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
-
Johnson & Johnson (JNJ) Announces FDA Issues Response Letter for Paliperidone Palmitate
-
The Medicines Company (MDCO) Announces Sub-Analysis Results
-
Deutsche Bank Notes Tysabri PML Patients are Recovering (BIIB, ELN)
-
Novavax (NVAX) Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
-
The Medicines Company (MDCO) Reports Results of VELOCITY Trial on Cleviprex(TM) in Annals of Emergency Medicine
-
Alsius (ALUS) Announces FDA Clearance to Market Solex(TM) Heat Exchange Catheter
-
Chelsea Therapeutics (CHTP) Announces FDA Fast Track Status
-
FDA Approves Amgen's (AMGN) Nplate(TM) for Adult Chronic ITP
-
FDA Approves Amgen's (AMGN) Bone Marrow Stimulator -DJ
-
OncoGenex Pharmaceuticals (OGXI) Receives FDA Fast Track Designation From OGX-011
-
Biogen Idec (BIIB) Initiates Phase III Clinical Trial for ADENTRI(R)
-
Telik's (TELK) Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
-
Telik's (TELK) Proteasome Inhibitor Program Meets a Preclinical Development Milestone
-
FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
-
AMAG Pharmaceuticals (AMG) Receives Fast Track Designation from FDA for Vascular-Enhanced Magnetic Resonance Imaging
-
FDA Wants More Data on Johnson & Johnson's (JNJ) Doribax Filing - AP
-
Home Diagnostics (HDIX) Announces FDA Clearance for TRUE2go, TRUEresult
-
St. Jude Medical (STJ) Receives FDA Approval for New Facility in Puerto Rico
-
C. R. Bard (BCR) Publishes Study Results of Agento(R) I.C. Endotracheal Tube in JAMA
-
Barr Pharmaceuticals (BRL) Receives Approval for Generic Aredia
-
Bristol-Myers Squibb (BMY) and PDL BioPharma (PDLI) Enter Agreement
-
CEL-SCI (CVM) In Licensing Agreement With Teva
-
Piper Jaffray Believes the Street Overreacted to Amylin's (AMLN) Pancreatitis Update
-
Medco Health Solutions (MHS) and FDA Enter Research Partnership
